ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis.
ALDOC
Breast cancer
ENO2
Glucose metabolism
Lung cancer
Metastasis
Omics
Tumor spheroids
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
22 Mar 2023
22 Mar 2023
Historique:
received:
07
10
2022
accepted:
07
03
2023
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
Metastases are the major cause of cancer-related morbidity and mortality. By the time cancer cells detach from their primary site to eventually spread to distant sites, they need to acquire the ability to survive in non-adherent conditions and to proliferate within a new microenvironment in spite of stressing conditions that may severely constrain the metastatic process. In this study, we gained insight into the molecular mechanisms allowing cancer cells to survive and proliferate in an anchorage-independent manner, regardless of both tumor-intrinsic variables and nutrient culture conditions. 3D spheroids derived from lung adenocarcinoma (LUAD) and breast cancer cells were cultured in either nutrient-rich or -restricted culture conditions. A multi-omics approach, including transcriptomics, proteomics, and metabolomics, was used to explore the molecular changes underlying the transition from 2 to 3D cultures. Small interfering RNA-mediated loss of function assays were used to validate the role of the identified differentially expressed genes and proteins in H460 and HCC827 LUAD as well as in MCF7 and T47D breast cancer cell lines. We found that the transition from 2 to 3D cultures of H460 and MCF7 cells is associated with significant changes in the expression of genes and proteins involved in metabolic reprogramming. In particular, we observed that 3D tumor spheroid growth implies the overexpression of ALDOC and ENO2 glycolytic enzymes concomitant with the enhanced consumption of glucose and fructose and the enhanced production of lactate. Transfection with siRNA against both ALDOC and ENO2 determined a significant reduction in lactate production, viability and size of 3D tumor spheroids produced by H460, HCC827, MCF7, and T47D cell lines. Our results show that anchorage-independent survival and growth of cancer cells are supported by changes in genes and proteins that drive glucose metabolism towards an enhanced lactate production. Notably, this finding is valid for all lung and breast cancer cell lines we have analyzed in different nutrient environmental conditions. broader Validation of this mechanism in other cancer cells of different origin will be necessary to broaden the role of ALDOC and ENO2 to other tumor types. Future in vivo studies will be necessary to assess the role of ALDOC and ENO2 in cancer metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Metastases are the major cause of cancer-related morbidity and mortality. By the time cancer cells detach from their primary site to eventually spread to distant sites, they need to acquire the ability to survive in non-adherent conditions and to proliferate within a new microenvironment in spite of stressing conditions that may severely constrain the metastatic process. In this study, we gained insight into the molecular mechanisms allowing cancer cells to survive and proliferate in an anchorage-independent manner, regardless of both tumor-intrinsic variables and nutrient culture conditions.
METHODS
METHODS
3D spheroids derived from lung adenocarcinoma (LUAD) and breast cancer cells were cultured in either nutrient-rich or -restricted culture conditions. A multi-omics approach, including transcriptomics, proteomics, and metabolomics, was used to explore the molecular changes underlying the transition from 2 to 3D cultures. Small interfering RNA-mediated loss of function assays were used to validate the role of the identified differentially expressed genes and proteins in H460 and HCC827 LUAD as well as in MCF7 and T47D breast cancer cell lines.
RESULTS
RESULTS
We found that the transition from 2 to 3D cultures of H460 and MCF7 cells is associated with significant changes in the expression of genes and proteins involved in metabolic reprogramming. In particular, we observed that 3D tumor spheroid growth implies the overexpression of ALDOC and ENO2 glycolytic enzymes concomitant with the enhanced consumption of glucose and fructose and the enhanced production of lactate. Transfection with siRNA against both ALDOC and ENO2 determined a significant reduction in lactate production, viability and size of 3D tumor spheroids produced by H460, HCC827, MCF7, and T47D cell lines.
CONCLUSIONS
CONCLUSIONS
Our results show that anchorage-independent survival and growth of cancer cells are supported by changes in genes and proteins that drive glucose metabolism towards an enhanced lactate production. Notably, this finding is valid for all lung and breast cancer cell lines we have analyzed in different nutrient environmental conditions. broader Validation of this mechanism in other cancer cells of different origin will be necessary to broaden the role of ALDOC and ENO2 to other tumor types. Future in vivo studies will be necessary to assess the role of ALDOC and ENO2 in cancer metastasis.
Identifiants
pubmed: 36945054
doi: 10.1186/s13046-023-02641-0
pii: 10.1186/s13046-023-02641-0
pmc: PMC10031988
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Lactates
0
ENO2 protein, human
EC 4.2.1.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Subventions
Organisme : Associazione italiana ricerca per il cancro (AIRC)
ID : IG24451
Organisme : Sapienza Università di Roma
ID : RP12117A7C149F70
Informations de copyright
© 2023. The Author(s).
Références
Cancer Res. 2021 Feb 1;81(3):567-579
pubmed: 33239425
Cell Death Dis. 2022 Jul 27;13(7):651
pubmed: 35896535
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
J Exp Clin Cancer Res. 2009 Oct 13;28:140
pubmed: 19825166
J Transl Med. 2015 May 07;13:144
pubmed: 25947346
Cell Cycle. 2015;14(14):2226-50
pubmed: 26030272
Toxicol Appl Pharmacol. 2018 Sep 15;355:180-188
pubmed: 30008376
Transl Oncol. 2020 Jun;13(6):100773
pubmed: 32334405
Cancer Res. 2005 Apr 15;65(8):3299-306
pubmed: 15833863
Int J Mol Sci. 2022 May 16;23(10):
pubmed: 35628385
Nat Rev Cancer. 2014 Sep;14(9):632-41
pubmed: 25098270
Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36
pubmed: 16971499
Oncotarget. 2021 Nov 23;12(24):2375-2387
pubmed: 34853659
Mol Cell Biol. 2009 May;29(10):2570-81
pubmed: 19273585
J Exp Clin Cancer Res. 2017 Aug 3;36(1):102
pubmed: 28774341
Cancers (Basel). 2019 May 29;11(6):
pubmed: 31146503
Cell Syst. 2018 Jul 25;7(1):49-62.e8
pubmed: 29960885
Int J Biol Markers. 2018 Jan;33(1):10-21
pubmed: 28885659
Cell Death Dis. 2018 Sep 20;9(10):970
pubmed: 30237463
J Exp Clin Cancer Res. 2021 Aug 24;40(1):265
pubmed: 34429143
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Front Oncol. 2021 Mar 29;11:626577
pubmed: 33854965
Neurobiol Dis. 2020 Jul;141:104880
pubmed: 32344152
PLoS One. 2016 Jan 22;11(1):e0147366
pubmed: 26799577
Oncogene. 2017 Jul 6;36(27):3797-3806
pubmed: 28218905
J Exp Clin Cancer Res. 2021 Mar 11;40(1):94
pubmed: 33706793
Leukemia. 2010 Aug;24(8):1533-7
pubmed: 20520633
J Vis Exp. 2021 May 8;(171):
pubmed: 34028441
J Chromatogr A. 2006 Aug 25;1125(1):76-88
pubmed: 16759663
Int J Mol Sci. 2017 Oct 17;18(10):
pubmed: 29039805
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cell Death Differ. 2009 Jul;16(7):939-46
pubmed: 19229244
FEBS Lett. 2014 Aug 25;588(17):3074-80
pubmed: 24952355
J Exp Clin Cancer Res. 2021 Jun 28;40(1):217
pubmed: 34183054
Transl Oncol. 2021 Apr;14(4):101039
pubmed: 33618068
Nat Protoc. 2012 Apr 12;7(5):872-81
pubmed: 22498707
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
J Exp Clin Cancer Res. 2021 Sep 28;40(1):305
pubmed: 34583759
Oncol Lett. 2019 Dec;18(6):5691-5698
pubmed: 31788041
J Exp Clin Cancer Res. 2019 May 23;38(1):218
pubmed: 31122265
Antioxidants (Basel). 2021 May 17;10(5):
pubmed: 34067882
Front Mol Biosci. 2021 Aug 11;8:719678
pubmed: 34458323
J Biol Chem. 2012 Dec 14;287(51):42554-63
pubmed: 23093405
PLoS One. 2007 Sep 05;2(9):e844
pubmed: 17786215
Mol Cell. 2017 Jun 15;66(6):772-779
pubmed: 28622522
J Cell Physiol. 2020 Mar;235(3):1877-1887
pubmed: 31397494
J Exp Clin Cancer Res. 2018 Jul 16;37(1):155
pubmed: 30012174
Oncogene. 2006 May 11;25(20):2901-8
pubmed: 16462772
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Nat Biotechnol. 2020 Mar;38(3):276-278
pubmed: 32055031
Acta Pharmacol Sin. 2021 Apr;42(4):633-640
pubmed: 32737469
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Oncol. 2020 Nov 02;10:1703
pubmed: 33224868
Cancer Sci. 2021 Jul;112(7):2884-2894
pubmed: 33934428
J Exp Clin Cancer Res. 2018 Mar 12;37(1):54
pubmed: 29530061
J Physiol. 2019 Jul;597(14):3561-3571
pubmed: 31116420
Nat Commun. 2012 Feb 14;3:672
pubmed: 22334075
Kidney Res Clin Pract. 2021 Dec;40(4):527-541
pubmed: 34781638
Adv Exp Med Biol. 1990;277:889-93
pubmed: 2096690
Front Oncol. 2022 Mar 31;12:868351
pubmed: 35433479
Acta Pharm Sin B. 2015 Sep;5(5):402-18
pubmed: 26579471
STAR Protoc. 2022 May 23;3(2):101283
pubmed: 35634361
J Exp Clin Cancer Res. 2018 Dec 17;37(1):318
pubmed: 30558661
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Oncotarget. 2016 Sep 20;7(38):62019-62033
pubmed: 27566559
Int J Mol Sci. 2020 Apr 28;21(9):
pubmed: 32354000
Adv Cancer Res. 2000;78:31-101
pubmed: 10547668
J Exp Clin Cancer Res. 2018 Jun 15;37(1):118
pubmed: 29907133
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Front Oncol. 2020 Jun 25;10:1010
pubmed: 32670883
Cancer Metab. 2020 Jul 10;8:16
pubmed: 32670573
Front Oncol. 2014 Sep 29;4:262
pubmed: 25325014
Nucleic Acids Res. 2008 Sep;36(16):5335-49
pubmed: 18689861
Mediators Inflamm. 2016;2016:8603164
pubmed: 28070145
Blood Adv. 2020 Aug 11;4(15):3594-3605
pubmed: 32761233
Genes Dev. 2011 Sep 15;25(18):1895-908
pubmed: 21937710
FEBS Lett. 2006 Nov 27;580(27):6447-54
pubmed: 17098234
Pathol Int. 2022 Mar;72(3):176-186
pubmed: 35147255
Cell Metab. 2017 Dec 5;26(6):842-855.e5
pubmed: 29056512
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
BMC Genomics. 2009 Aug 07;10:365
pubmed: 19660143
BMC Cancer. 2018 Feb 27;18(1):222
pubmed: 29482503
Cell Death Dis. 2019 Jan 17;10(2):40
pubmed: 30674873
F1000Res. 2017 Sep 22;6:1724
pubmed: 29034085
Proteins. 2005 Oct 1;61(1):213-6
pubmed: 16080146
Mol Med Rep. 2021 May;23(5):
pubmed: 33760124
Onco Targets Ther. 2020 Feb 14;13:1375-1396
pubmed: 32110039
J Exp Clin Cancer Res. 2021 Sep 30;40(1):308
pubmed: 34593007
J Exp Clin Cancer Res. 2018 Apr 17;37(1):84
pubmed: 29665843
Oncogene. 2017 Aug 10;36(32):4573-4584
pubmed: 28368399
Cell Mol Biol (Noisy-le-grand). 2017 Nov 30;63(11):75-85
pubmed: 29208177
J Exp Clin Cancer Res. 2018 Sep 15;37(1):228
pubmed: 30219064
J Exp Clin Cancer Res. 2022 Jan 21;41(1):29
pubmed: 35063003
Br J Cancer. 2022 Sep;127(5):800-810
pubmed: 35484215
J Cell Mol Med. 2011 May;15(5):1044-53
pubmed: 21129150
Oral Dis. 2021 Mar;27(2):193-203
pubmed: 32645756
J Exp Clin Cancer Res. 2017 Dec 13;36(1):183
pubmed: 29237483
J Exp Clin Cancer Res. 2018 Apr 23;37(1):87
pubmed: 29688867
Cancer Lett. 2017 Oct 10;406:93-104
pubmed: 28797843
Metab Brain Dis. 2016 Jun;31(3):487-95
pubmed: 26847611
Cell Metab. 2019 Oct 1;30(4):754-767.e9
pubmed: 31422903
Mol Cell. 2021 Sep 16;81(18):3760-3774
pubmed: 34547237
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Mol Cell Proteomics. 2020 Feb;19(2):421-430
pubmed: 31888964
Front Oncol. 2021 Mar 15;11:642761
pubmed: 33791226
PLoS One. 2016 Sep 22;11(9):e0163078
pubmed: 27657916
J Exp Clin Cancer Res. 2020 Nov 30;39(1):267
pubmed: 33256814
Biomed Pharmacother. 2021 Jun;138:111536
pubmed: 34311534
Mol Cancer Res. 2019 Oct;17(10):2089-2101
pubmed: 31308147
PLoS One. 2016 Mar 16;11(3):e0151359
pubmed: 26982978
J Exp Clin Cancer Res. 2020 Jul 6;39(1):126
pubmed: 32631382
Cancer Res. 2016 Mar 1;76(5):1044-54
pubmed: 26676754
J Exp Clin Cancer Res. 2015 Oct 06;34:111
pubmed: 26445347
Mutat Res. 2011 Jul-Oct;728(1-2):23-34
pubmed: 21605699
Gene. 2018 May 30;657:92-99
pubmed: 29544765
Front Oncol. 2020 May 05;10:698
pubmed: 32432042
Cell Death Dis. 2021 Jun 18;12(7):629
pubmed: 34145217
Haematologica. 2018 Feb;103(2):361-372
pubmed: 29079593
Bioinformatics. 2020 Apr 15;36(8):2611-2613
pubmed: 31909781